Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Abstract: This disclosure features methods and compositions for treating inflammatory disorders or conditions that arise in a tissue originating from the endoderm using an immune modulator.

Abstract: The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK or other kinase inhibitor.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Abstract: Various embodiments are described herein for a device, system, and method for identifying a location of an ingestible device within a gastrointestinal tract of a body. In some embodiments, the ingestible device includes a sensing unit with an axial optical sensing sub-unit located proximal to at least one end of the device, and a radial optical sensing sub-unit located proximal to a radial wall of the device, and may autonomously identify a location within the gastrointestinal tract. In some embodiments, the ingestible device includes optical illumination sources and detectors that operate at a plurality of different wavelengths, and may discern regions of a gastrointestinal tract by using the reflection properties of organ tissue and occasional particulates. In some embodiments, the ingestible device may sample fluid or release medicament based on a detected device location.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immune modulatory agent (e.g., a CD40/CD40L inhibitor).

Abstract: The present disclosure relates to gastrointestinal (GI) tract detection methods, devices and systems.

Abstract: Various embodiments are described herein for a device, system, and method for identifying a location of an ingestible device within a gastrointestinal tract of a body. In some embodiments, the ingestible device includes a sensing unit with an axial optical sensing sub-unit located proximal to at least one end of the device, and a radial optical sensing sub-unit located proximal to a radial wall of the device, and may autonomously identify a location within the gastrointestinal tract. In some embodiments, the ingestible device includes optical illumination sources and detectors that operate at a plurality of different wavelengths, and may discern regions of a gastrointestinal tract by using the reflection properties of organ tissue and occasional particulates. In some embodiments, the ingestible device may sample fluid or release medicament based on a detected device location.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: An ingestible device, includes a storage reservoir configured to store a dispensable substance and a pressurized chamber configured so that, when a restraining force is removed from the pressurized clamber, the dispensable substance exits the ingestible device via openings in the ingestible device.

Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: Ingestible devices are disclosed that provide very high localization accuracy for the devices when present in the GI tract of a body. Related systems and methods are also disclosed.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a JAK inhibitor.

Abstract: Ingestible devices capable of delivering a dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are disclosed. A removably attachable storage reservoir configured to be used with an ingestible device and capable of storing dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are also disclosed.

Abstract: Ingestible devices capable of delivering a dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are disclosed. A removably attachable storage reservoir configured to be used with an ingestible device and capable of storing dispensable substance, such as, for example, a therapeutic agent, as well as related components, systems and methods, are also disclosed.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with an immunosuppressant.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with a TNF-alpha inhibitor.

Abstract: Ingestible devices can directly deliver therapeutic agents to desired tissue(s) of the GI tract of a subject, such as the submucosa, the mucosa, and/or the mucus layer of the GI tract, and methods of using the same. The ingestible devices can deliver therapeutic agents in a safe, effective, and reliable manner. The disclosure also provides pharmaceutical compositions for use in methods of treating a disease or condition in a subject in need thereof.

Abstract: This disclosure features methods and compositions for treating diseases of the gastrointestinal tract with IL-10 or an IL-10 agonist.